PapersFlow Research Brief
Metabolism, Diabetes, and Cancer
Research Guide
What is Metabolism, Diabetes, and Cancer?
Metabolism, Diabetes, and Cancer is the interdisciplinary study of metabolic dysregulation in diabetes and its links to cancer through pathways like AMPK activation, insulin resistance, glucose metabolism, and drugs such as metformin.
This field examines AMP-activated protein kinase (AMPK) regulation of glucose and lipid metabolism, insulin signaling, mitochondrial homeostasis, and metformin-mediated gene expression changes, with 58,225 papers published. Key works include Matthews et al. (1985) introducing the homeostasis model assessment for insulin resistance and β-cell function, cited 30,921 times. Vander Heiden et al. (2009) explained the Warburg effect in tumor cell proliferation, cited 15,601 times.
Topic Hierarchy
Research Sub-Topics
AMPK Regulation of Glucose Metabolism
This sub-topic covers the mechanisms by which AMP-activated protein kinase (AMPK) controls glucose uptake, glycogen synthesis, and homeostasis. Researchers study its role in insulin sensitivity and diabetes prevention.
AMPK in Lipid Metabolism and Mitochondrial Homeostasis
This sub-topic examines AMPK's influence on fatty acid oxidation, lipogenesis, and mitochondrial biogenesis. Researchers investigate its protective effects against metabolic disorders.
Metformin Activation of AMPK Signaling
This sub-topic focuses on how metformin activates AMPK pathways to restore cellular energy balance. Researchers explore its downstream effects on gene expression and insulin signaling.
AMPK and Tumor Suppression in Cancer
This sub-topic investigates AMPK's role in inhibiting cell proliferation and promoting autophagy in cancer cells. Researchers link its activation to reduced cancer risk via metabolic reprogramming.
Insulin Resistance and AMPK Dysregulation
This sub-topic studies how impaired AMPK activity contributes to insulin resistance in diabetes. Researchers examine links to inflammation and oxidative stress in metabolic tissues.
Why It Matters
Metformin activation of AMPK reduces type 2 diabetes incidence by 31% in high-risk individuals compared to placebo, as shown in the Diabetes Prevention Program by Knowler et al. (2002), with 18,734 citations. Empagliflozin lowers cardiovascular mortality in type 2 diabetes patients at high risk, reducing the primary composite outcome versus placebo in the EMPA-REG trial by Zinman et al. (2015), with 11,536 citations. Intensive glucose control with metformin sustains microvascular risk reduction and cuts myocardial infarction risk over 10 years, per Holman et al. (2008), while insulin resistance drives disease progression in 25% of nonobese individuals with normal glucose tolerance, as detailed by Reaven (1988).
Reading Guide
Where to Start
'Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man' by Matthews et al. (1985) first, as it provides the foundational metric for quantifying insulin resistance central to diabetes and metabolic links to cancer.
Key Papers Explained
Matthews et al. (1985) established insulin resistance assessment, which Reaven (1988) expanded to disease mechanisms in 'Role of Insulin Resistance in Human Disease.' Knowler et al. (2002) applied metformin intervention in 'Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin,' building on these to show prevention. Vander Heiden et al. (2009) connected to cancer via 'Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,' while Mootha et al. (2003) linked diabetes to mitochondrial genes in 'PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.' Holman et al. (2008) provided long-term data in '10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes.'
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research focuses on AMPK's role in mitochondrial homeostasis and gene expression, as in the cluster description, with metformin effects on tumor suppression unexplored in recent preprints. No new preprints or news in the last 6-12 months indicate steady progress via established pathways like insulin signaling and glucose metabolism.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Homeostasis model assessment: insulin resistance and ?-cell fu... | 1985 | Diabetologia | 30.9K | ✓ |
| 2 | Reduction in the Incidence of Type 2 Diabetes with Lifestyle I... | 2002 | New England Journal of... | 18.7K | ✓ |
| 3 | Understanding the Warburg Effect: The Metabolic Requirements o... | 2009 | Science | 15.6K | ✓ |
| 4 | Role of Insulin Resistance in Human Disease | 1988 | Diabetes | 12.1K | ✕ |
| 5 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type ... | 2015 | New England Journal of... | 11.5K | ✓ |
| 6 | Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle... | 2001 | New England Journal of... | 10.8K | ✓ |
| 7 | PGC-1α-responsive genes involved in oxidative phosphorylation ... | 2003 | Nature Genetics | 10.3K | ✕ |
| 8 | THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH ... | 1963 | Biochemical Journal | 10.2K | ✓ |
| 9 | mTOR Signaling in Growth Control and Disease | 2012 | Cell | 8.3K | ✓ |
| 10 | 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes | 2008 | New England Journal of... | 7.6K | ✓ |
Frequently Asked Questions
What is the homeostasis model assessment?
The homeostasis model assessment estimates insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations. Matthews et al. (1985) developed this model in 'Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,' cited 30,921 times. It applies to patients with impaired glucose tolerance and non-insulin-dependent diabetes.
How does metformin prevent type 2 diabetes?
Metformin reduces type 2 diabetes incidence in high-risk persons through AMPK activation and improved cellular energy balance. Knowler et al. (2002) showed in 'Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin' that it was less effective than lifestyle changes but still preventive, with 18,734 citations. This links to its role in glucose metabolism regulation.
What is the Warburg effect?
The Warburg effect describes tumor cells' preference for glycolysis over mitochondrial respiration for energy during proliferation. Vander Heiden et al. (2009) detailed this in 'Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,' cited 15,601 times. It connects metabolic shifts in cancer to diabetes-related dysregulation.
What role does insulin resistance play in disease?
Insulin resistance impairs glucose uptake and appears in most impaired glucose tolerance cases, non-insulin-dependent diabetes, and 25% of nonobese normal glucose tolerant individuals. Reaven (1988) outlined this in 'Role of Insulin Resistance in Human Disease,' cited 12,088 times. It underlies metabolic links to cancer risk.
How does PGC-1α relate to diabetes?
PGC-1α-responsive genes for oxidative phosphorylation are downregulated in human diabetes. Mootha et al. (2003) demonstrated this coordination in 'PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes,' cited 10,299 times. It highlights mitochondrial homeostasis defects.
What are long-term benefits of glucose control?
Intensive glucose control reduces microvascular risk and myocardial infarction despite glycemic differences fading. Holman et al. (2008) reported in '10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes' continued benefits with metformin in overweight patients, cited 7,626 times. Lifestyle changes also prevent diabetes in high-risk subjects.
Open Research Questions
- ? How does AMPK activation by metformin specifically suppress tumor growth beyond glucose control?
- ? What mechanisms link PGC-1α downregulation in diabetes to increased cancer risk via mitochondrial dysfunction?
- ? Can mTOR inhibition address insulin resistance-driven proliferation in diabetes-associated cancers?
- ? Which downstream effectors of insulin signaling most directly elevate cancer risk in insulin-resistant states?
- ? How do Warburg effect adaptations in cancer cells interact with diabetes-induced metabolic stress?
Recent Trends
The field spans 58,225 works with high citation classics like Matthews et al. at 30,921 citations, but growth rate data is unavailable.
1985No preprints in the last 6 months or news in 12 months suggests consolidation around AMPK, metformin, and Warburg effect insights from top papers like Vander Heiden et al. .
2009Research Metabolism, Diabetes, and Cancer with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Metabolism, Diabetes, and Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers